Literature DB >> 20351807

Anovulation and ovulation induction.

I Katsikis1, M Kita, A Karkanaki, N Prapas, D Panidis.   

Abstract

Conventional treatment of normogonadotropic anovulatory infertility is ovulation induction using the antiestrogen clomiphene citrate, followed by follicle-stimulating hormone. Multiple follicle development, associated with ovarian hyperstimulation, and multiple pregnancy remain the major complications. Cumulative singleton and multiple pregnancy rate data after different induction treatments are needed. Newer ovulation induction interventions, such as insulin-sensitizing drugs, aromatase inhibitors and laparoscopic ovarian electrocoagulation, should be compared with conventional treatments. Ovulation induction efficiency might improve if patient subgroups with altered chances for success or complications with new or conventional techniques could be identified, using multivariate prediction models based on initial screening characteristics. This would make ovulation induction more cost-effective, safe and convenient, enabling doctors to advise patients on the most effective and patient-tailored treatment strategy.

Entities:  

Keywords:  anovulation; gonadotropins; infertility; ovarian hyperstimulation syndrome; ovulation induction

Year:  2006        PMID: 20351807      PMCID: PMC2808395     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  75 in total

Review 1.  Anovulation.

Authors:  Diana Hamilton-Fairley; Alison Taylor
Journal:  BMJ       Date:  2003-09-06

Review 2.  Peptides in the brain: the new endocrinology of the neuron.

Authors:  R Guillemin
Journal:  Science       Date:  1978-10-27       Impact factor: 47.728

3.  Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence.

Authors:  H Matsuo; Y Baba; R M Nair; A Arimura; A V Schally
Journal:  Biochem Biophys Res Commun       Date:  1971-06-18       Impact factor: 3.575

Review 4.  Clomiphene citrate--end of an era? A mini-review.

Authors:  Roy Homburg
Journal:  Hum Reprod       Date:  2005-05-05       Impact factor: 6.918

Review 5.  The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.

Authors:  Sophie Jonard; Didier Dewailly
Journal:  Hum Reprod Update       Date:  2004 Mar-Apr       Impact factor: 15.610

6.  HUMAN HYPOPHYSEAL GONADOTROPIN IN HYPOPHYSECTOMIZED WOMEN.

Authors:  G BETTENDORF
Journal:  Int J Fertil       Date:  1963 Oct-Dec

7.  Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.

Authors:  Evanthia Diamanti-Kandarakis; Thomas Paterakis; Krystallenia Alexandraki; Christina Piperi; Athanasios Aessopos; Ilias Katsikis; Nikolaos Katsilambros; George Kreatsas; Dimitrios Panidis
Journal:  Hum Reprod       Date:  2006-02-23       Impact factor: 6.918

8.  Ovulation induction using laparoscopic ovarian drilling in women with polycystic ovarian syndrome: predictors of success.

Authors:  S A K Amer; T C Li; W L Ledger
Journal:  Hum Reprod       Date:  2004-06-03       Impact factor: 6.918

9.  Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH).

Authors:  W F Crowley; J W McArthur
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958

10.  Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome.

Authors:  E Greenblatt; R F Casper
Journal:  Am J Obstet Gynecol       Date:  1987-02       Impact factor: 8.661

View more
  2 in total

1.  Impact of IVF on the Timing and Symptoms of Menopause.

Authors:  R Muharam; Kanadi Sumapraja; Gita Pratama; Mazaya Azyati; Kevin Ardito Prabowo
Journal:  Int J Womens Health       Date:  2021-09-22

Review 2.  Anti-Inflammatory Diets in Fertility: An Evidence Review.

Authors:  Simon Alesi; Anthony Villani; Evangeline Mantzioris; Wubet Worku Takele; Stephanie Cowan; Lisa J Moran; Aya Mousa
Journal:  Nutrients       Date:  2022-09-21       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.